Desferri‐Exochelin, A Lipid Soluble Iron Chelator Effectively Removes Tissue Iron
نویسندگان
چکیده
منابع مشابه
Iron chelator drugs in thalassemia,a review article
Abstract Thalassemia syndromes are the most common inherited hemoglobinopathies in the world characterized by various degrees of defective production of the alpha or beta globin chains. Impairment in alpha chain or beta chain synthesis leads to alpha thalassemia and beta thalassemia syndromes respectively. Iran is one of the countries located on the thalassemia belt therefore this disease is ...
متن کاملOral iron chelator L1 and autoimmunity.
As Brittenham’ has reviewed in detail, the use of the oral iron chelator LI has been associated with significant clinical and animal toxicity. One of the more controversial issues surrounding the human use of LI has been the possible development of autoimmune phenomena as manifested by development of autoantibodies such as antinuclear antibodies (ANA). The Canadian group investigating LI did no...
متن کاملHydroxyurea Could Be a Good Clinically Relevant Iron Chelator
Our previous study showed a reduction in serum ferritin of β-thalassemia patients on hydroxyurea therapy. Here we aimed to evaluate the efficacy of hydroxyurea alone and in combination with most widely used iron chelators like deferiprone and deferasirox for reducing iron from experimentally iron overloaded mice. 70 BALB/c mice received intraperitonial injections of iron-sucrose. The mice were ...
متن کاملProteomic profiling reveals that collismycin A is an iron chelator
Collismycin A (CMA), a microbial product, has anti-proliferative activity against cancer cells, but the mechanism of its action remains unknown. Here, we report the identification of the molecular target of CMA by ChemProteoBase, a proteome-based approach for drug target identification. ChemProteoBase profiling showed that CMA is closely clustered with di-2-pyridylketone 4,4-dimethyl-3-thiosemi...
متن کاملDeferasirox: a novel, once-daily oral iron chelator
10.1586/14750708.3.4.453 © 2 Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload since humans do not possess a physiological mechanism for removing excess iron. Without appropriate treatment, the cumulative effects of iron overload lead to severe organ damage and, ultimately, death. The iron chelating agent, deferoxamine, has been used effectively for...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FASEB Journal
سال: 2006
ISSN: 0892-6638,1530-6860
DOI: 10.1096/fasebj.20.4.a231-c